Poorly Differentiated Sarcoma

Lili Duda, VMD
Ultima Vez Modificado: 1 de noviembre del 2001

Share article


Question
Dear OncoLink "Ask the Experts,"
Our 11-year-old miniature schnauzer recently had a biopsy to remove a mass on his front leg. The diagnosis was: "Poorly differentiated sarcoma, possible fibrosarcoma". The veterinarian has recommended amputation as quickly as possible. This seems so radical since the report was "possible fibrosarcoma". If we decide against amputation, what would be the advisable alternatives and their potential for success?


Answer
Lili Duda, VMD, Editor of the OncoLink Veterinary Oncology Section, responds:

I'd like to clarify the interpretation of the biospy results. As written, they indicate that the mass is definitely a kind of cancer called a sarcoma. The "possible fibrosarcoma" means that while it is definitely a sarcoma, it is difficult to determine what type of sarcoma, and that fibrosarcoma is the pathologist's best guess. In general, poorly differentiated tumors mean that the tumor cells are so malignant that it is impossible to determine the normal tissue type from which the tumor is derived. This is a poor prognostic indicator because poorly differentiated tumors are more likely to be locally aggressive and to metastasize (that is, spread elsewhere in the body) than are well-differentiated tumors.

Before any treatment is undertaken, it is advisable to evaluate the regional lymph nodes (by at least fine needle aspiration and cytology). Chest X-rays are also advisable to look for evidence of tumor spread. Amputation is the best option for local control of the tumor, particularly if it is large. A second option would be surgical "debulking" IF this is possible followed by radiation therapy to eliminate residual cancer cells. The benefit of adding chemotherapy to the treatments listed above is unknown at this time.

If you or your veterinarian have not already done so, please consult a qualified veterinary oncologist to further explore the treatment options for your pet.



News
ROR2 ID'd As Novel Biomarker of Soft-Tissue Sarcomas

Jan 18, 2012 - ROR2 gene mutations are expressed in a subset of soft-tissue sarcomas, including leiomyosarcoma, gastrointestinal stromal tumors, and desmoid-type fibromatosis, and expression may be indicative of poor prognosis, according to a study published online Jan. 4 in The Journal of Pathology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información